Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells

BACKGROUND: Current immune checkpoint blockade strategies have been successful in treating certain types of solid cancer. However, checkpoint blockade monotherapies have not been successful against most hematological malignancies including multiple myeloma and leukemia. There is an urgent need to id...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Heyu, Chen, Yuanzhi, Deng, Mi, John, Samuel, Gui, Xun, Kansagra, Ankit, Chen, Weina, Kim, Jaehyup, Lewis, Cheryl, Wu, Guojin, Xie, Jingjing, Zhang, Lingbo, Huang, Ryan, Liu, Xiaoye, Arase, Hisashi, Huang, Yang, Yu, Hai, Luo, Wenxin, Xia, Ningshao, Zhang, Ningyan, An, Zhiqiang, Zhang, Cheng Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418854/
https://www.ncbi.nlm.nih.gov/pubmed/32771992
http://dx.doi.org/10.1136/jitc-2019-000515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418854/
https://www.ncbi.nlm.nih.gov/pubmed/32771992
http://dx.doi.org/10.1136/jitc-2019-000515

Ejemplares similares